Navigation Links
Arpida Enrols First Patients in "Intravenous-to-Oral" Switch Trial With Oral Iclaprim
Date:5/26/2008

REINACH, Switzerland, May 26 /PRNewswire-FirstCall/ -- Arpida Ltd (SWX: ARPN) today announced the enrolment of the first patients into the Phase II "intravenous-to-oral" switch trial with oral iclaprim in complicated Skin and Skin Structure Infections (cSSSI). Enrolment remains on track for completion in 2008.

The key objective of the study is to assess the clinical efficacy of an oral capsule formulation of iclaprim as step-down therapy in comparison with a full course of intravenous (i.v.) treatment with vancomycin in the treatment of cSSSI. The primary endpoint will be the clinical cure rate at the Test-of-Cure (TOC) visit. Secondary objectives include bacteriological outcomes as well as safety and tolerability.

This Phase II trial is designed as a multi-centre, double-blind, double-dummy comparative study. Patients suffering from cSSSI receive i.v. vancomycin for the first two days of treatment and are then randomised to either continue to receive i.v. vancomycin or to be switched to oral iclaprim for eight additional days. A total of 60 patients will be randomised for this study.

Dr Paul Hadvary, Head of Development of Arpida Ltd., commented: "Among the hospital anti-MRSA drugs that are currently in filing or late-stage development, only iclaprim shows oral bioavailability allowing clinical development and consequently offers the potential for intravenous-to-oral switch therapy. We consider the oral switch therapy to be an important option addressing an increasing therapeutic need. It allows patients to be sent home earlier, thereby increasing patient comfort, reducing the risk of contracting additional infections and lowering costs for the healthcare system. We feel the oral switch therapy could add significant potential to the intravenous formulation."

About Arpida Ltd.

Arpida (SWX: ARPN) is a biopharmaceutical company with research facilities in Reinach, Switzerland and in the USA. It focuses on the discovery and dev
'/>"/>

SOURCE Arpida Ltd.
Copyright©2008 PR Newswire.
All rights reserved

0

GOOD

Page: 1 2 3

Related medicine technology :

1. Arpida Invited to Present Data on Iclaprim at Scientific Conference
2. Arpida Provides Further Comments on the Pivotal Phase III Trials
3. Reclast(R) Receives US FDA Approval as First and Only Once-Yearly Treatment for Women With Postmenopausal Osteoporosis
4. Sixty-One Percent of Newly Diagnosed Parkinsons Disease Patients Do Not Receive Any Drug Treatment in the First Year of Diagnosis
5. Xenomics Announces Implementation of its First Diagnostic Test for Acute Myeloid Leukemia Into Clinical Practice
6. GlaxoSmithKline Receives New HHS Order for H5N1 Bulk Antigen. First North American Clinical Trials with GSKs Candidate Pre-pandemic Flu Vaccine to Start.
7. Video: Landmark Study in The Lancet: Patients Treated With Betaseron(R) After First MS Attack Experienced Significant Delay in MS Progression
8. Peregrine Pharmaceuticals Doses First Patient in Cotara(R) Phase II Brain Cancer Trial In India
9. Tainted Chinese Food Ingredients First Discovered in 2005
10. First Patient Enrolled in Europe in Ovature Phase III Ovarian Cancer Trial
11. Protalix BioTherapeutics Treats First Patient in Phase III Clinical Trial of prGCD
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/19/2013)... , June 19, 2013   BioCision ... sample standardization and handling in many areas of ... of new patents by the U.S. Patent Office ... products developed to standardize sample handling to ensure ... results in common laboratory procedures. ...
(Date:6/19/2013)... , June 19, 2013 /PRNewswire/ ... has recently added DrugPatentWatch to its ... http://www.bharatbook.com/drugpatentwatch-tour.pdf )      (Logo: ... comprehensive information on pharmaceutical, drug patents ... supports the critical business functions of ...
(Date:6/19/2013)... , June 19, 2013 Amerivet Solutions, ... servicing all branches of government from Federal to ... expanded their facilities to include complex metal design ... fabricated some very complex aluminum parts for the ... expand our capabilities to service government contracts," states ...
Breaking Medicine Technology:BioCision Announces Two New U.S. Patents for Thermo-Conductive Products that Standardize Sample Handling in Laboratory Research 2Drug Patent Watch 2Drug Patent Watch 3Amerivet Solutions Expands to Manufacture Complex Metal Designs 2
(Date:6/19/2013)... 19, 2013 Strict rules for ... 2013, Orriant is launching a new tool to ... compliance with regulations. New HHS regulations will ... incentives if their employer offers outcome-based, health-contingent, compliant ... compliant with these standards for nearly a decade. ...
(Date:6/19/2013)... As Januvia lawsuit ... in courts throughout the U.S., Bernstein Liebhard LLP notes ... held a meeting to discuss the safety of Januvia ... According to a June 12th report from Bloomberg.com, the ... Januvia and similar drugs, following a recent study that ...
(Date:6/19/2013)... (June 19, 2013) In what is believed to ... most common form of hereditary dystonia a movement ... in deep brain stimulation report good success rates and ... the Movement Disorders Program at Cedars-Sinai Medical Center,s Department ... the Division of Neurosurgery at Beth Israel Deaconess Medical ...
(Date:6/19/2013)... reveals significant disparities between minority and white clients ... programs. Moreover, these disparities vary widely from state ... for most states there,s something amiss," says Stephan ... "There are strong racial and ethnic disparities for ... treatment programs successfully, and those disparities are something ...
(Date:6/19/2013)... 19, 2013 The Movement ... neurosurgeons, psychiatrists and urologists with specialists in physical ... works with patients and their family members to ... of life. Patients also have the opportunity to ... research. , “Movement disorders can be relentlessly progressive ...
Breaking Medicine News(10 mins):Health News:New Tool to Increase Participation Rates for Corporate Wellness Programs in July 2013 Will Help Maintain Compliance with Federal Regulations 2Health News:New Tool to Increase Participation Rates for Corporate Wellness Programs in July 2013 Will Help Maintain Compliance with Federal Regulations 3Health News:Januvia Lawsuit News: Bernstein Liebhard LLP Comments on Recent FDA Meeting to Discuss Safety of Januvia and Other Incretin Mimetics 2Health News:Januvia Lawsuit News: Bernstein Liebhard LLP Comments on Recent FDA Meeting to Discuss Safety of Januvia and Other Incretin Mimetics 3Health News:Long-term study reports deep brain stimulation effective for most common hereditary dystonia 2Health News:States vary widely on success rates for minorities in drug treatment programs 2Health News:States vary widely on success rates for minorities in drug treatment programs 3Health News:Abington Memorial Hospital’s Neurosciences Institute Opens Movement Disorders Center 2
... Industries, a,leading manufacturer of specialty vehicles in the United ... production facility in Bluffton,Ohio. Company officials plan to move ... Hutchinson, Kansas by November 9, 2007. "The closure ... was,certainly a difficult decision. Since the purchase of this ...
... Center Suite operates with Gryphon compliance services ... resulting in increased productivity for call centers, ... provider of,intelligent customer interaction solutions, today announced that ... the worldwide leader in,On-Demand Contact Governance solutions. This ...
... of pen-and-paper questionnaires/ , Here is a great ... soon be obsolete! Well, at least for people with ... by doctors. Thanks to the RT3 accelerometer, MS patients ... keeping a journal or completing activity questionnaires. The RT3 ...
... took a weekly dose of risedronate, sold as Actonel, ... take the drug, according to a two-year study from ... week at the 29th annual meeting of the American ... through Wednesday at the Hawaii Convention Center. , Susan ...
... More Than 30 years of Healthcare Management Expertise, ... leader in,Provider Network Management solutions, today announced the ... PacifiCare of California, to its board,of directors. ... of the country,s,largest HMOs is a tremendous asset ...
... In the face of an emerging liver cancer crisis in ... developed a test that could help millions. Due to widespread ... population is at high risk for hepatocellular carcinoma (HCC), a ... treated early. Researchers report on a new blood screening ...
Cached Medicine News:Health News:Company Announces Closure of Bluffton, Ohio Plant 2Health News:Amcat Partners With Gryphon to Provide Comprehensive and Guaranteed Do Not Call (DNC) Compliance Solution for Outbound Contact Activities 2Health News:Amcat Partners With Gryphon to Provide Comprehensive and Guaranteed Do Not Call (DNC) Compliance Solution for Outbound Contact Activities 3Health News:Story tips for journalists 2Health News:Story tips for journalists 3Health News:Weekly dose of osteoporosis drug prevents bone loss after breast cancer treatment 2Health News:Jon R. Wampler Joins Portico Systems' Board of Directors 2Health News:Liver cancer marker could yield blood test for early detection 2Health News:Liver cancer marker could yield blood test for early detection 3Health News:Liver cancer marker could yield blood test for early detection 4
... national reference laboratory and a worldwide leader ... offers an extensive test menu of highly ... and anatomic pathology. Owned by the University ... than half of the nation's university teaching ...
... national reference laboratory and a worldwide leader ... offers an extensive test menu of highly ... and anatomic pathology. Owned by the University ... than half of the nation's university teaching ...
... ARUP Laboratories is a national reference ... laboratory research and development. ARUP offers an ... unique medical tests in clinical and anatomic ... ARUP Laboratories' clients include more than half ...
... a national reference laboratory and a worldwide ... ARUP offers an extensive test menu of ... clinical and anatomic pathology. Owned by the ... more than half of the nation's university ...
Medicine Products: